These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

636 related items for PubMed ID: 17157164

  • 21. Inhibition of 90-kD heat shock protein potentiates the cytotoxicity of chemotherapeutic agents in human glioma cells.
    Ohba S, Hirose Y, Yoshida K, Yazaki T, Kawase T.
    J Neurosurg; 2010 Jan; 112(1):33-42. PubMed ID: 19408974
    [Abstract] [Full Text] [Related]

  • 22. Akt shows variable sensitivity to an Hsp90 inhibitor depending on cell context.
    Theodoraki MA, Kunjappu M, Sternberg DW, Caplan AJ.
    Exp Cell Res; 2007 Nov 01; 313(18):3851-8. PubMed ID: 17643429
    [Abstract] [Full Text] [Related]

  • 23. 17-Allylamino-17-demethoxygeldanamycin and ritonavir inhibit renal cancer growth by inhibiting the expression of heat shock factor-1.
    Sato A, Asano T, Ito K, Asano T.
    Int J Oncol; 2012 Jul 01; 41(1):46-52. PubMed ID: 22470109
    [Abstract] [Full Text] [Related]

  • 24. Synergistic interaction between 17-AAG and phosphatidylinositol 3-kinase inhibition in human malignant glioma cells.
    Premkumar DR, Arnold B, Jane EP, Pollack IF.
    Mol Carcinog; 2006 Jan 01; 45(1):47-59. PubMed ID: 16267832
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Coadministration of the heat shock protein 90 antagonist 17-allylamino- 17-demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells.
    Rahmani M, Yu C, Dai Y, Reese E, Ahmed W, Dent P, Grant S.
    Cancer Res; 2003 Dec 01; 63(23):8420-7. PubMed ID: 14679005
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma.
    Francis LK, Alsayed Y, Leleu X, Jia X, Singha UK, Anderson J, Timm M, Ngo H, Lu G, Huston A, Ehrlich LA, Dimmock E, Lentzsch S, Hideshima T, Roodman GD, Anderson KC, Ghobrial IM.
    Clin Cancer Res; 2006 Nov 15; 12(22):6826-35. PubMed ID: 17121904
    [Abstract] [Full Text] [Related]

  • 30. Combination of rapamycin and 17-allylamino-17-demethoxygeldanamycin abrogates Akt activation and potentiates mTOR blockade in breast cancer cells.
    Roforth MM, Tan C.
    Anticancer Drugs; 2008 Aug 15; 19(7):681-8. PubMed ID: 18594209
    [Abstract] [Full Text] [Related]

  • 31. [Gene Expression Profile of Apoptosis in Leukemia Cells Induced by Hsp90 Selective inhibitor 17-AAG].
    Wang NN, Li ZH, Tao YF, Xu LX, Pan J, Hu SY.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Jun 15; 24(3):672-80. PubMed ID: 27342489
    [Abstract] [Full Text] [Related]

  • 32. Requirement for a hsp90 chaperone-dependent MEK1/2-ERK pathway for B cell antigen receptor-induced cyclin D2 expression in mature B lymphocytes.
    Piatelli MJ, Doughty C, Chiles TC.
    J Biol Chem; 2002 Apr 05; 277(14):12144-50. PubMed ID: 11823472
    [Abstract] [Full Text] [Related]

  • 33. Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. See: E. A. Sausville, Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters, Clin. Cancer Res., 7: 2155-2158, 2001.
    Münster PN, Basso A, Solit D, Norton L, Rosen N.
    Clin Cancer Res; 2001 Aug 05; 7(8):2228-36. PubMed ID: 11489796
    [Abstract] [Full Text] [Related]

  • 34. P53-dependent radiosensitizing effects of Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin on human oral squamous cell carcinoma cell lines.
    Shintani S, Zhang T, Aslam A, Sebastian K, Yoshimura T, Hamakawa H.
    Int J Oncol; 2006 Nov 05; 29(5):1111-7. PubMed ID: 17016641
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers.
    Chandarlapaty S, Sawai A, Ye Q, Scott A, Silinski M, Huang K, Fadden P, Partdrige J, Hall S, Steed P, Norton L, Rosen N, Solit DB.
    Clin Cancer Res; 2008 Jan 01; 14(1):240-8. PubMed ID: 18172276
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Inhibition of Hsp90 leads to cell cycle arrest and apoptosis in human malignant pleural mesothelioma.
    Okamoto J, Mikami I, Tominaga Y, Kuchenbecker KM, Lin YC, Bravo DT, Clement G, Yagui-Beltran A, Ray MR, Koizumi K, He B, Jablons DM.
    J Thorac Oncol; 2008 Oct 01; 3(10):1089-95. PubMed ID: 18827603
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 32.